Boosting DNA vaccine power by lipid nanoparticles surface engineered with amphiphilic bioresorbable copolymer

IF 6.5 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Molecular Therapy. Nucleic Acids Pub Date : 2024-06-17 DOI:10.1016/j.omtn.2024.102261
Chung-Hsiang Yang, Kuan-Yin Shen, Hui-Min Ho, Chiung-Yi Huang, Yu-Jhen Cheng, Chih-Chun Pu, Fang-Feng Chiu, Wan-Chun Huang, Hung-Chun Liao, Hsin-Wei Chen, Ching-Len Liao, Shih-Jen Liu, Ming-Hsi Huang
{"title":"Boosting DNA vaccine power by lipid nanoparticles surface engineered with amphiphilic bioresorbable copolymer","authors":"Chung-Hsiang Yang, Kuan-Yin Shen, Hui-Min Ho, Chiung-Yi Huang, Yu-Jhen Cheng, Chih-Chun Pu, Fang-Feng Chiu, Wan-Chun Huang, Hung-Chun Liao, Hsin-Wei Chen, Ching-Len Liao, Shih-Jen Liu, Ming-Hsi Huang","doi":"10.1016/j.omtn.2024.102261","DOIUrl":null,"url":null,"abstract":"Successful DNA vaccination generally requires the aid of either a viral vector within vaccine components or an electroporation device into the muscle or skin of the host. However, these systems come with certain obstacles, including limited transgene capacity, broad preexisting immunity in humans, and substantial cell death caused by high voltage pulses, respectively. In this study, we repurposed the use of an amphiphilic bioresorbable copolymer (ABC), called PLA-PEG, as a surface engineering agent that conciliates lipid nanoparticles (LNPs) between stability during preparation and biocompatibility post-vaccination. The LNP carrier can be loaded with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific DNA; in this form, the DNA-LNP is immunogenic in hamsters and elicits protective immunity following DNA-LNP vaccination against heterologous virus challenge or as a hybrid-type vaccine booster against SARS-CoV-2 variants. The data provide comprehensive information on the relationships between LNP composition, manufacturing process, and vaccine efficacy. The outcomes of this study offer new insights into designing next-generation LNP formulations and pave the way for boosting vaccine power to combat existing and possible emerging infectious diseases/pathogens.","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":"9 1","pages":""},"PeriodicalIF":6.5000,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2024.102261","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Successful DNA vaccination generally requires the aid of either a viral vector within vaccine components or an electroporation device into the muscle or skin of the host. However, these systems come with certain obstacles, including limited transgene capacity, broad preexisting immunity in humans, and substantial cell death caused by high voltage pulses, respectively. In this study, we repurposed the use of an amphiphilic bioresorbable copolymer (ABC), called PLA-PEG, as a surface engineering agent that conciliates lipid nanoparticles (LNPs) between stability during preparation and biocompatibility post-vaccination. The LNP carrier can be loaded with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific DNA; in this form, the DNA-LNP is immunogenic in hamsters and elicits protective immunity following DNA-LNP vaccination against heterologous virus challenge or as a hybrid-type vaccine booster against SARS-CoV-2 variants. The data provide comprehensive information on the relationships between LNP composition, manufacturing process, and vaccine efficacy. The outcomes of this study offer new insights into designing next-generation LNP formulations and pave the way for boosting vaccine power to combat existing and possible emerging infectious diseases/pathogens.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用两亲性生物可吸收共聚物对脂质纳米粒子进行表面工程处理,增强 DNA 疫苗的威力
成功的 DNA 疫苗接种通常需要借助疫苗成分中的病毒载体,或将电穿孔装置植入宿主的肌肉或皮肤。然而,这些系统都存在一定的障碍,包括转基因能力有限、人类原有免疫力广泛、高压脉冲导致大量细胞死亡等。在这项研究中,我们将一种名为聚乳酸-聚乙二醇(PLA-PEG)的两亲性生物可吸收共聚物(ABC)重新用作表面工程剂,使脂质纳米粒子(LNPs)在制备过程中的稳定性和接种后的生物相容性之间取得平衡。这种 LNP 载体可装载严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)尖峰特异性 DNA;在这种形式下,DNA-LNP 对仓鼠具有免疫原性,并在接种 DNA-LNP 疫苗后对异源病毒挑战或作为针对 SARS-CoV-2 变体的混合型疫苗增强剂产生保护性免疫。这些数据提供了有关 LNP 成分、生产工艺和疫苗功效之间关系的全面信息。这项研究的成果为设计下一代 LNP 制剂提供了新的见解,并为增强疫苗能力以对抗现有和可能出现的传染病/病原体铺平了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
15.40
自引率
1.10%
发文量
336
审稿时长
20 weeks
期刊介绍: Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.
期刊最新文献
Retraction Notice to: Promotion of tumor progression by exosome transmission of circular RNA circSKA3. siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations. miR-125b differentially impacts mineralization in dexamethasone and calcium-treated human mesenchymal stem cells. Unleashing the TLR9-driven multilineage differentiation of myeloid leukemia cells in vivo. Extracellular viral microRNAs as biomarkers of virus infection in human cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1